Cantor Fitzgerald Weighs in on MNMD FY2026 Earnings

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for Mind Medicine (MindMed) in a note issued to investors on Monday, June 9th. Cantor Fitzgerald analyst C. Duncan forecasts that the company will post earnings of ($1.72) per share for the year. Cantor Fitzgerald has a "Strong-Buy" rating on the stock. The consensus estimate for Mind Medicine (MindMed)'s current full-year earnings is ($1.35) per share.

Mind Medicine (MindMed) (NASDAQ:MNMD - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.35) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.01.

A number of other equities analysts have also recently commented on MNMD. Robert W. Baird lowered their price target on Mind Medicine (MindMed) from $27.00 to $16.00 and set an "outperform" rating for the company in a report on Friday, March 7th. HC Wainwright reiterated a "buy" rating and issued a $55.00 target price on shares of Mind Medicine (MindMed) in a research report on Friday, March 7th. Finally, Chardan Capital reissued a "buy" rating and issued a $20.00 target price on shares of Mind Medicine (MindMed) in a report on Friday, May 9th. Eight investment analysts have rated the stock with a buy rating and three have assigned a strong buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and an average price target of $25.50.

Mind Medicine (MindMed) Price Performance

MNMD traded down $0.13 during trading on Tuesday, hitting $7.17. 985,843 shares of the stock traded hands, compared to its average volume of 1,360,771. The business has a 50 day moving average price of $6.60 and a 200 day moving average price of $6.95. The company has a market cap of $541.72 million, a price-to-earnings ratio of -3.17 and a beta of 2.52. Mind Medicine has a twelve month low of $4.70 and a twelve month high of $10.44. The company has a debt-to-equity ratio of 0.09, a current ratio of 9.00 and a quick ratio of 9.00.

Insider Buying and Selling at Mind Medicine (MindMed)

In other news, CEO Robert Barrow sold 21,208 shares of the firm's stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $6.74, for a total transaction of $142,941.92. Following the completion of the transaction, the chief executive officer now owns 856,556 shares of the company's stock, valued at approximately $5,773,187.44. This trade represents a 2.42% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Daniel Karlin sold 6,836 shares of the stock in a transaction on Tuesday, March 25th. The shares were sold at an average price of $6.74, for a total value of $46,074.64. Following the completion of the sale, the insider now owns 446,177 shares of the company's stock, valued at $3,007,232.98. The trade was a 1.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 30,391 shares of company stock worth $204,835. 2.45% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Rhumbline Advisers raised its position in shares of Mind Medicine (MindMed) by 7.7% during the first quarter. Rhumbline Advisers now owns 108,457 shares of the company's stock worth $634,000 after acquiring an additional 7,762 shares during the last quarter. AWM Investment Company Inc. grew its holdings in Mind Medicine (MindMed) by 1.3% during the 1st quarter. AWM Investment Company Inc. now owns 1,208,162 shares of the company's stock worth $7,068,000 after acquiring an additional 15,000 shares during the period. Ally Bridge Group NY LLC grew its stake in Mind Medicine (MindMed) by 18.1% during the first quarter. Ally Bridge Group NY LLC now owns 390,143 shares of the company's stock worth $2,282,000 after purchasing an additional 59,868 shares during the period. Royal Bank of Canada increased its holdings in Mind Medicine (MindMed) by 10.4% in the first quarter. Royal Bank of Canada now owns 65,237 shares of the company's stock worth $382,000 after purchasing an additional 6,148 shares in the last quarter. Finally, DRW Securities LLC acquired a new position in Mind Medicine (MindMed) in the first quarter valued at approximately $292,000. 27.91% of the stock is owned by institutional investors and hedge funds.

Mind Medicine (MindMed) Company Profile

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.